Previous close | 34.83 |
Open | 38.38 |
Bid | 41.34 x N/A |
Ask | 42.40 x N/A |
Day's range | 42.24 - 39.08 |
52-week range | 2.11 - 39.08 |
Volume | |
Avg. volume | 16 |
Market cap | 5.266B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 31 July 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Adaptive Biotechnologies ( NASDAQ:ADPT ) First Quarter 2024 Results Key Financial Results Revenue: US$41.9m (up 11...
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024. “This quarter, we implemented important decisions to maximize the value of our MRD and Immune Medicine businesses. I am confident in the steps w
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Ti